Unlock stock picks and a broker-level newsfeed that powers Wall Street.

Shenzhen - Delayed Quote CNY

Luyan Pharma Co.,Ltd. (002788.SZ)

8.03
-0.04
(-0.50%)
At close: April 30 at 3:04:51 PM GMT+8
Loading Chart for 002788.SZ
  • Previous Close 8.07
  • Open 8.08
  • Bid 8.02 x --
  • Ask 8.03 x --
  • Day's Range 8.01 - 8.13
  • 52 Week Range 6.88 - 9.56
  • Volume 3,750,150
  • Avg. Volume 4,703,826
  • Market Cap (intraday) 3.12B
  • Beta (5Y Monthly) --
  • PE Ratio (TTM) 9.45
  • EPS (TTM) 0.85
  • Earnings Date --
  • Forward Dividend & Yield 0.30 (3.74%)
  • Ex-Dividend Date Jul 4, 2024
  • 1y Target Est --

Luyan Pharma Co.,Ltd. distributes and sells medicines, Chinese herbal medicines, medical devices, and vaccines in China. It also operates pharmaceutical retail chains. The company was formerly known as Luyan (Fujian) Pharma Co. Ltd. and changed its name to Luyan Pharma Co.,Ltd. in June 2016. Luyan Pharma Co.,Ltd. was founded in 2008 and is headquartered in Xiamen, China.

www.luyan.com.cn

--

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 002788.SZ

View More

Performance Overview: 002788.SZ

Trailing total returns as of 4/30/2025, which may include dividends or other distributions. Benchmark is SSE Composite Index (000001.SS) .

YTD Return

002788.SZ
2.19%
SSE Composite Index (000001.SS)
2.17%

1-Year Return

002788.SZ
5.74%
SSE Composite Index (000001.SS)
5.61%

3-Year Return

002788.SZ
22.42%
SSE Composite Index (000001.SS)
7.61%

5-Year Return

002788.SZ
17.50%
SSE Composite Index (000001.SS)
14.65%

Compare To: 002788.SZ

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 002788.SZ

View More

Valuation Measures

Annual
As of 4/30/2025
  • Market Cap

    3.12B

  • Enterprise Value

    7.79B

  • Trailing P/E

    9.45

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    0.15

  • Price/Book (mrq)

    0.96

  • Enterprise Value/Revenue

    0.38

  • Enterprise Value/EBITDA

    12.10

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    1.62%

  • Return on Assets (ttm)

    3.41%

  • Return on Equity (ttm)

    10.59%

  • Revenue (ttm)

    20.51B

  • Net Income Avi to Common (ttm)

    333.19M

  • Diluted EPS (ttm)

    0.85

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    457.88M

  • Total Debt/Equity (mrq)

    157.33%

  • Levered Free Cash Flow (ttm)

    246M

Research Analysis: 002788.SZ

View More

Company Insights: 002788.SZ

Research Reports: 002788.SZ

View More

People Also Watch